10:30:14 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-06-20 Ordinarie utdelning AXIC A 0.00 SEK
2024-06-19 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-06 Extra Bolagsstämma 2024
2024-03-05 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-19 Ordinarie utdelning AXIC A 0.00 SEK
2023-06-16 Årsstämma 2023
2023-05-24 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2022-05-31 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning AXIC A 0.00 SEK
2021-05-28 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning AXIC A 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning AXIC A 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2018-05-31 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-24 Ordinarie utdelning AXIC A 0.00 SEK
2016-05-23 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-25 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning AXIC A 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-25 Kvartalsrapport 2015-Q1
2015-02-26 Bokslutskommuniké 2014
2014-11-24 Kvartalsrapport 2014-Q3
2014-08-28 Kvartalsrapport 2014-Q2
2014-05-22 Årsstämma 2014
2014-05-22 Kvartalsrapport 2014-Q1
2014-02-28 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-08-26 Kvartalsrapport 2013-Q2
2013-06-28 Split AXIC A 4:1
2013-05-30 Kvartalsrapport 2013-Q1
2013-05-21 Ordinarie utdelning AXIC A 0.00 SEK
2013-05-20 Årsstämma 2013
2013-02-28 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-30 Kvartalsrapport 2012-Q2
2012-05-28 Kvartalsrapport 2012-Q1
2012-05-17 Ordinarie utdelning AXIC A 0.00 SEK
2012-05-16 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-28 Kvartalsrapport 2011-Q3
2011-08-30 Kvartalsrapport 2011-Q2
2011-05-30 Kvartalsrapport 2011-Q1
2011-05-10 Ordinarie utdelning AXIC A 0.00 SEK
2011-05-09 Årsstämma 2011
2011-02-25 Bokslutskommuniké 2010
2010-05-11 Ordinarie utdelning AXIC A 0.00 SEK

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorMaterial
IndustriPlast, kemikalier & fetter
aXichem är verksamt inom industriell bioteknik. Bolaget utvecklar, patenterar och marknadsför industrikemikalier. Bolaget arbetar framförallt med Fenylcapsaicin, en naturanalog syntetisk capsaicin med tillämpningar inom en mängd olika områden, såsom inom den marina sektorn, bland skadedjursbekämpning i skogs-och jordbruk, samt bland enskilda farmaceutiska arbetsområden. Verksamhet drivs på global nivå, med huvudkontoret i Malmö.
2023-04-24 08:15:00

aXichem AB (https://www.axichem.com/) (publ), (aXichem), a provider of innovative natural analogue ingredients to the nutraceutical market, today announces that a scientific article describing the study "Effects of different phenylcapsaicin doses on resistance training performance, muscle damage, protein breakdown, metabolic response, ratings of perceived exertion and recovery: A randomized, triple-blinded, placebo-controlled, crossover trial." (https://www.tandfonline.com/doi/full/10.1080/15502783.2023.2204083) has been published in Journal of the International Society of Sports Nutrition (https://jissn.biomedcentral.com/) (JISSN). The published study was sponsored by aXichem and carried out in 2022, in collaboration with the Spanish companies LIFEPro Nutrition (https://www.lifepronutrition.com/es/) and Indiex Sport Nutrition (http://indiex.es/) and conducted at University of Pablo Olavide (https://www.upo.es/intl/the-university/?lang=en) - High Performance Center (CIRFED), which is one of the most prestigious universities related to resistance training worldwide.

The main finding of the study, which included twenty-five trained male athletes in a full squat velocity performance setting, was that a high dose (2.5 mg) of phenylcapsaicin reduced ratings of perceived exertion of the active muscle and enhanced mechanical performance in combination with exhibiting an effect of lower muscle damage in comparison to placebo or a low dose (0.625 mg) of phenylcapsaicin. Specifically, high dose was associated with significant faster velocities in squat, lower active muscle rating of perceived exertion, and lower levels of aspartate aminotransferase (https://www.cigna.com/knowledge-center/hw/medical-tests/aspartate-aminotransferase-test-hw20331) (a biomarker for muscle damage) at 24-hour post-exercise compared to low dose and placebo.

"This study shows that phenylcapsaicin reduces the perception of fatigue and allows the athletes to train harder with maintained velocity, making more repetitions, until failure, possible. The data also show that phenylcapsaicin reduces muscle damage after work out. These combined data from the study are very exciting and show us that phenylcapsaicin has a significant potential as an ingredient in innovative products for training and fitness. A higher dose consumer product is also commercially very exciting for aXichem. This is a growing market, driven by an increased awareness of how a healthy lifestyle can positively impact your wellness. Consumers' general knowledge of nutritional supplements and their demand for more reliably data on the ingredients also work to our advantage," says Torsten Helsing, CEO of aXichem.

Alejandro Monedero Gimeno, Managing Director at LIFEPro Nutrition comments:

"These exciting results show that phenylcapsaicin has a great potential. Our intention is to launch two new products containing aXivite in the Spanish market later this year. Spain is one of the top five markets in Europe when it comes to sports nutrition products, and the interest in health and training keep growing." 
 

Raza Bashir, Vice president of Scientific Affairs and Product Innovation at Iovate comments:

"We are thrilled to see yet another strong scientific message from our partner aXichem. aXivite offers unique properties that align perfectly with our commitment to delivering high-quality and effective active nutrition and weight management products. We believe that our joint product plan for this year will add significant value to our customers and support their fitness goals."

Read the full article

"Effects of different phenylcapsaicin doses on resistance training performance, muscle damage, protein breakdown, metabolic response and recovery: A randomized, triple-blinded, placebo-controlled, crossover trial." (https://www.tandfonline.com/doi/full/10.1080/15502783.2023.2204083)

Authors: Pablo Jiménez-Martínez, Pedro Jesús Cornejo-Daza, Juan Sánchez-Valdepeñas , Iván Asín-Izquierdo, Clara Cano-Castillo, Carlos Alix-Fages, Fernando Pareja-Blanco[ ]Juan C. Colado

The information was submitted, through the care of the contact person, for publication on 24 April 2023, at 08:15 AM CEST.